The company said, “Crysvita revenue to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx (RARE) will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023. Dojolvi revenue to be in the range of $75 million to $80 million Net Cash Used in Operations of around $400 million.”